These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 16224277)

  • 1. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
    Blansfield JA; Beck KE; Tran K; Yang JC; Hughes MS; Kammula US; Royal RE; Topalian SL; Haworth LR; Levy C; Rosenberg SA; Sherry RM
    J Immunother; 2005; 28(6):593-8. PubMed ID: 16224277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
    Kaehler KC; Egberts F; Lorigan P; Hauschild A
    Melanoma Res; 2009 Oct; 19(5):333-4. PubMed ID: 19512947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
    Phan GQ; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; Duray PH; Steinberg SM; Allison JP; Davis TA; Rosenberg SA
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8372-7. PubMed ID: 12826605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
    Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
    J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
    Robinson MR; Chan CC; Yang JC; Rubin BI; Gracia GJ; Sen HN; Csaky KG; Rosenberg SA
    J Immunother; 2004; 27(6):478-9. PubMed ID: 15534492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
    Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
    Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
    Phan GQ; Weber JS; Sondak VK
    Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.
    Dillard T; Yedinak CG; Alumkal J; Fleseriu M
    Pituitary; 2010; 13(1):29-38. PubMed ID: 19639414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
    Jaber SH; Cowen EW; Haworth LR; Booher SL; Berman DM; Rosenberg SA; Hwang ST
    Arch Dermatol; 2006 Feb; 142(2):166-72. PubMed ID: 16490844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
    Iwama S; De Remigis A; Callahan MK; Slovin SF; Wolchok JD; Caturegli P
    Sci Transl Med; 2014 Apr; 6(230):230ra45. PubMed ID: 24695685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
    Kähler KC; Hauschild A
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.
    Maker AV; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Hughes M; Yellin MJ; Haworth LR; Levy C; Allen T; Mavroukakis SA; Attia P; Rosenberg SA
    J Immunother; 2006; 29(4):455-63. PubMed ID: 16799341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease.
    Torino F; Barnabei A; De Vecchis L; Salvatori R; Corsello SM
    Oncologist; 2012; 17(4):525-35. PubMed ID: 22477725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
    Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
    Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
    Attia P; Phan GQ; Maker AV; Robinson MR; Quezado MM; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Restifo NP; Haworth LR; Levy C; Mavroukakis SA; Nichol G; Yellin MJ; Rosenberg SA
    J Clin Oncol; 2005 Sep; 23(25):6043-53. PubMed ID: 16087944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series.
    Caturegli P; Di Dalmazi G; Lombardi M; Grosso F; Larman HB; Larman T; Taverna G; Cosottini M; Lupi I
    Am J Pathol; 2016 Dec; 186(12):3225-3235. PubMed ID: 27750046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of immune-related adverse events and kinetics of response with ipilimumab.
    Weber JS; Kähler KC; Hauschild A
    J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
    Sanderson K; Scotland R; Lee P; Liu D; Groshen S; Snively J; Sian S; Nichol G; Davis T; Keler T; Yellin M; Weber J
    J Clin Oncol; 2005 Feb; 23(4):741-50. PubMed ID: 15613700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
    Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
    Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.